4M Therapeutics Strengthens Executive Leadership Team with Appointment of Kimberly Lee, D.O. as Chief Business Officer [Yahoo! Finance]
Taysha Gene Therapies, Inc. (TSHA)
Company Research
Source: Yahoo! Finance
SKILLMAN, N.J., March 04, 2024 BUSINESS WIRE )--4M Therapeutics Inc., an early-stage biotechnology company developing treatments for neuropsychiatric and neurodegenerative conditions, today announced the appointment of Kimberly Lee, D.O. as Chief Business Officer and member of the executive management team. Dr. Lee has over 20 years of biotechnology industry and Wall Street experience with expertise in financial and corporate strategy across a broad range of therapeutic areas including CNS, oncology, nephrology, pain and metabolic and rare diseases. "We are excited to welcome Kim to the team to maximize the potential of our pipeline and to drive strategic growth," said Dr. Pablo Lapuerta, Chief Executive Officer and Co-founder of 4M Therapeutics. "Her experience will be instrumental as we enter the next phase of the company's life cycle." Over the past year, Dr. Lee collaborated with 4M Therapeutics as a strategic advisor, providing tactical input and support to the Company's man
Show less
Read more
Impact Snapshot
Event Time:
TSHA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TSHA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TSHA alerts
High impacting Taysha Gene Therapies, Inc. news events
Weekly update
A roundup of the hottest topics
TSHA
News
- Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $7.00 price target on the stock.MarketBeat
- Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q1 Earnings? What You Should Know [Yahoo! Finance]Yahoo! Finance
- Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome [Yahoo! Finance]Yahoo! Finance
- Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett SyndromeGlobeNewswire
TSHA
Earnings
- 11/14/23 - Miss
TSHA
Sec Filings
- 4/18/24 - Form DEFA14A
- 4/18/24 - Form ARS
- 4/18/24 - Form DEF
- TSHA's page on the SEC website